Finnish adult ADHD patient found medical cannabis more helpful than Ritalin over five years

After experiencing adverse effects from methylphenidate and alternative medications, the patient was prescribed Bedrocan (THC-dominant) for ADHD symptom relief and Bediol (THC+CBD) to moderate the THC effects and improve sleep. Over 5 years, the THC-dominant product helped with frustration tolerance, anger outbursts, boredom, and concentration.

Detailed single-patient case report with sociological framing, describing a patient's journey from methylphenidate to medical cannabis for adult ADHD, prescribed through Germany and confirmed by Finnish neurologist. Includes brief literature review of cannabis for ADHD.

ADHD treatment in adults relies heavily on stimulant medications that many patients cannot tolerate. This detailed case adds to limited evidence that some ADHD patients may benefit from cannabinoid therapeutics, particularly for emotional regulation symptoms.

A Lancet review cited in the memory found no effect of cannabinoids for ADHD in small trials. This case report suggests the disconnect may be between group-level trial results and individual patient responses, highlighting the need for personalized approaches.

Single case report, the weakest evidence level. Patient self-reported outcomes without objective measures. No placebo comparison. The patient sought cannabinoid treatment actively, suggesting potential bias. Regulatory and cultural context (Finland) may affect generalizability.